ESPR Relative Valuation
ESPR's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, ESPR is overvalued; if below, it's undervalued.
Historical Valuation
Esperion Therapeutics Inc (ESPR) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -1.97. The fair price of Esperion Therapeutics Inc (ESPR) is between NaN to NaN according to relative valuation methord.
Relative Value
Fair Zone
NaN-NaN
Current Price：3.80
Fair
12.55
PE
1Y
3Y
5Y
Trailing
Forward
8.78
EV/EBITDA
Esperion Therapeutics Inc. (ESPR) has a current EV/EBITDA of 8.78. The 5-year average EV/EBITDA is 11.74. The thresholds are as follows: Strongly Undervalued below -208.23, Undervalued between -208.23 and -98.25, Fairly Valued between 121.73 and -98.25, Overvalued between 121.73 and 231.72, and Strongly Overvalued above 231.72. The current Forward EV/EBITDA of 8.78 falls within the Historic Trend Line -Fairly Valued range.
8.56
EV/EBIT
Esperion Therapeutics Inc. (ESPR) has a current EV/EBIT of 8.56. The 5-year average EV/EBIT is -4.42. The thresholds are as follows: Strongly Undervalued below -26.11, Undervalued between -26.11 and -15.26, Fairly Valued between 6.43 and -15.26, Overvalued between 6.43 and 17.27, and Strongly Overvalued above 17.27. The current Forward EV/EBIT of 8.56 falls within the Overvalued range.
1.86
PS
Esperion Therapeutics Inc. (ESPR) has a current PS of 1.86. The 5-year average PS is 3.14. The thresholds are as follows: Strongly Undervalued below -2.13, Undervalued between -2.13 and 0.51, Fairly Valued between 5.77 and 0.51, Overvalued between 5.77 and 8.41, and Strongly Overvalued above 8.41. The current Forward PS of 1.86 falls within the Historic Trend Line -Fairly Valued range.
14.61
P/OCF
Esperion Therapeutics Inc. (ESPR) has a current P/OCF of 14.61. The 5-year average P/OCF is -0.01. The thresholds are as follows: Strongly Undervalued below -20.69, Undervalued between -20.69 and -10.35, Fairly Valued between 10.32 and -10.35, Overvalued between 10.32 and 20.66, and Strongly Overvalued above 20.66. The current Forward P/OCF of 14.61 falls within the Overvalued range.
9.40
P/FCF
Esperion Therapeutics Inc. (ESPR) has a current P/FCF of 9.40. The 5-year average P/FCF is -1.93. The thresholds are as follows: Strongly Undervalued below -16.33, Undervalued between -16.33 and -9.13, Fairly Valued between 5.27 and -9.13, Overvalued between 5.27 and 12.47, and Strongly Overvalued above 12.47. The current Forward P/FCF of 9.40 falls within the Overvalued range.
Esperion Therapeutics Inc (ESPR) has a current Price-to-Book (P/B) ratio of -1.72. Compared to its 3-year average P/B ratio of -0.88 , the current P/B ratio is approximately 94.54% higher. Relative to its 5-year average P/B ratio of -0.19, the current P/B ratio is about 785.33% higher. Esperion Therapeutics Inc (ESPR) has a Forward Free Cash Flow (FCF) yield of approximately 0.00%. Compared to its 3-year average FCF yield of -49.35%, the current FCF yield is approximately -100.00% lower. Relative to its 5-year average FCF yield of -51.73% , the current FCF yield is about -100.00% lower.
-1.72
P/B
Median3y
-0.88
Median5y
-0.19
-10.48
FCF Yield
Median3y
-49.35
Median5y
-51.73
Competitors Valuation Multiple
The average P/S ratio for ESPR's competitors is 0.00, providing a benchmark for relative valuation. Esperion Therapeutics Inc Corp (ESPR) exhibits a P/S ratio of , which is NaN% above the industry average. Given its robust revenue growth of 69.10%, this premium appears sustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
Performance Decomposition
1Y
3Y
5Y
Market capitalization of ESPR increased by 72.27% over the past 1 year. The primary factor behind the change was an increase in Revenue Growth from 51.63M to 87.31M.
The secondary factor is the P/E Change, contributed 40.40%to the performance.
Overall, the performance of ESPR in the past 1 year is driven by Revenue Growth. Which is more sustainable.
People Also Watch
FAQ
Is Esperion Therapeutics Inc (ESPR) currently overvalued or undervalued?
What is Esperion Therapeutics Inc (ESPR) fair value?
How does ESPR's valuation metrics compare to the industry average?
What is the current P/B ratio for Esperion Therapeutics Inc (ESPR) as of Dec 05 2025?
What is the current FCF Yield for Esperion Therapeutics Inc (ESPR) as of Dec 05 2025?
What is the current Forward P/E ratio for Esperion Therapeutics Inc (ESPR) as of Dec 05 2025?